StreetInsider.com News Articles

Form 4 FIREFLY NEUROSCIENCE, For: Sep 25 Filed by: Vnook Stella

Tue, 29 Sep 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260929/27122702.html

Form 4 FIREFLY NEUROSCIENCE, For: Sep 25 Filed by: POSNER BRIAN M

Tue, 29 Sep 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260929/27122687.html

Form 4 FIREFLY NEUROSCIENCE, For: Sep 25 Filed by: Menawat Arun Swarup

Tue, 29 Sep 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260929/27122676.html

Firefly and NeuroSigma partner to expand pediatric ADHD treatment

Fri, 25 Sep 2026 07:45:36 -0400

Firefly Neuroscience (NASDAQ: AIFF) and NeuroSigma announced a partnership to distribute NeuroSigma's Monarch eTNS® System through Firefly's nationwide network of Evoke™ clinicians, according to a press release dated Sept. 25, 2026.

The Monarch eTNS® System is the first non-drug treatment for pediatric attention-deficit/hyperactivity disorder cleared by the U.S. Food and Drug Administration. The prescription-only device delivers mild external trigeminal nerve stimulation through an adhesive patch placed on a child's forehead during sleep. It is cleared as a monotherapy for children ages 7 through 12 who are not currently taking prescription ADHD medication.

NeuroSigma began U.S. sales of its second-generation Monarch device in

Firefly and NeuroSigma partner to expand pediatric ADHD treatment

Fri, 25 Sep 2026 07:45:36 -0400

NeuroSigma began U.S. sales of its second-generation Monarch device in

Firefly (NASDAQ: AIFF) and NeuroSigma Partner to Expand Access to First FDA-Cleared, Non-Drug Treatment for Pediatric ADHD

Fri, 25 Sep 2026 07:45:00 -0400

– Partnership will introduce NeuroSigma’s second-generation Monarch eTNS^® System to Firefly’s nationwide network of Evoke™ clinicians –

– Collaboration brings together an FDA-cleared pediatric ADHD treatment and Firefly’s objective brain-function assessment platform and AI-driven ADHD biomarker research –

– Monarch offers an at-home, non-medication treatment option for eligible children ages 7 through 12 ––

KENMORE, N.Y. and LOS ANGELES, Sept. 25, 2026 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly”) (NASDAQ: AIFF), an artificial intelligence (“AI”) company advancing precision neuroscience, and NeuroSigma, Inc. (“NeuroSigma”), a bioelectronic medical device company, today announced a

Firefly (NASDAQ: AIFF) and NeuroSigma Partner to Expand Access to First FDA-Cleared, Non-Drug Treatment for Pediatric ADHD

Fri, 25 Sep 2026 07:45:00 -0400

– Partnership will introduce NeuroSigma’s second-generation Monarch eTNS^® System to Firefly’s nationwide network of Evoke™ clinicians –

– Collaboration brings together an FDA-cleared pediatric ADHD treatment and Firefly’s objective brain-function assessment platform and AI-driven ADHD biomarker research –

– Monarch offers an at-home, non-medication treatment option for eligible children ages 7 through 12 ––

Firefly Neuroscience to integrate EEG platform with Radial's clinic network

Thu, 17 Sep 2026 07:51:05 -0400

Firefly Neuroscience, Inc. (NASDAQ: AIFF) announced a strategic collaboration with Radial to pursue integration of Firefly's FDA 510(k)-cleared Evoke™ EEG/ERP platform with RadialOS, Radial's proprietary operating system for brain medicine, according to a press release dated Sept. 17, 2026.

The planned integration would incorporate objective brain-function data into Radial's diagnostic workflow, allowing clinicians to identify treatment pathways and track patient outcomes over time. Radial operates a network of 27 clinics across seven states, supporting therapies including transcranial magnetic stimulation, medications, and other interventional approaches.

Firefly's Evoke™ platform combines quantitative electroencephalography and event-related potential testing with AI-powered analytics. The platform is designed to

Firefly Neuroscience’s Evoke™ Platform Selected to Bring Objective Brain-Function Insights to Radial’s AI-Native Operating System for Brain Medicine

Thu, 17 Sep 2026 07:50:00 -0400

– This integration of Firefly’s FDA 510(k)-cleared, AI-powered EEG/ERP technology follows Radial’s August 2026 acquisition of the management services organization supporting Mindful Health Solutions, forming the country’s largest brain medicine clinical network –

KENMORE, N.Y. and NEW YORK, Sept. 17, 2026 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly”) (NASDAQ: AIFF) today announced a strategic collaboration with Radial, operator of the country’s largest network of brain medicine clinics, to pursue the integration of Firefly’s FDA 510(k)-cleared, AI-powered Evoke™ EEG/ERP platform with RadialOS, Radial’s proprietary AI-native operating system for brain medicine.

The planned

Firefly Neuroscience’s Evoke™ Platform Selected to Bring Objective Brain-Function Insights to Radial’s AI-Native Operating System for Brain Medicine

Thu, 17 Sep 2026 07:50:00 -0400

The planned

Form 3 FIREFLY NEUROSCIENCE, For: Sep 08 Filed by: Paz Jessica Lucia

Mon, 14 Sep 2026 16:56:00 -0400

si-local-file:///var/storage/secattach/20260914/27059105.html

Form 8-K FIREFLY NEUROSCIENCE, For: Sep 08

Mon, 14 Sep 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20260914/27058811.html

Form 10-Q FIREFLY NEUROSCIENCE, For: Jun 30

Tue, 11 Aug 2026 06:01:00 -0400

si-local-file:///var/storage/secattach/20260811/26900375.html

Form 10-Q FIREFLY NEUROSCIENCE, For: Jun 30

Tue, 11 Aug 2026 06:01:00 -0400

si-local-file:///var/storage/secattach/20260811/26900375.html

Form 8-K FIREFLY NEUROSCIENCE, For: Aug 05

Fri, 07 Aug 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260807/26891550.html

Form 8-K FIREFLY NEUROSCIENCE, For: Aug 05

Fri, 07 Aug 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260807/26891550.html

Firefly Neuroscience (NASDAQ: AIFF) Reports 291% Increase in TMS Center Customer Brain Scan Volumes

Wed, 05 Aug 2026 07:45:00 -0400

Commercial momentum continues to build, while Firefly harnesses increased electrophysiological data combining EEG and ERG to unlock future value

KENMORE, N.Y., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence ("AI") company advancing precision neuroscience, today announced a close to four-fold (291%) year-over-year increase in Transcranial Magnetic Stimulation (“TMS”) center customer clinical assessments using its U.S. Food and Drug Administration (“FDA”) 510(k)-cleared, AI-powered EEG/ERP platform, Evoke™.

By combining qEEG and ERP, Evoke™ provides a more complete view of brain activity, designed to help clinicians identify patterns, differentiate

Firefly Neuroscience (NASDAQ: AIFF) Reports 291% Increase in TMS Center Customer Brain Scan Volumes

Wed, 05 Aug 2026 07:45:00 -0400

Commercial momentum continues to build, while Firefly harnesses increased electrophysiological data combining EEG and ERG to unlock future value

By combining qEEG and ERP, Evoke™ provides a more complete view of brain activity, designed to help clinicians identify patterns, differentiate

Firefly Neuroscience (NASDAQ: AIFF) Reports 291% Increase in TMS Center Customer Brain Scan Volumes

Wed, 05 Aug 2026 07:45:00 -0400

Commercial momentum continues to build, while Firefly harnesses increased electrophysiological data combining EEG and ERG to unlock future value

By combining qEEG and ERP, Evoke™ provides a more complete view of brain activity, designed to help clinicians identify patterns, differentiate

Firefly Neuroscience (NASDAQ: AIFF) Reports 291% Increase in TMS Center Customer Brain Scan Volumes

Wed, 05 Aug 2026 07:45:00 -0400

Commercial momentum continues to build, while Firefly harnesses increased electrophysiological data combining EEG and ERG to unlock future value

By combining qEEG and ERP, Evoke™ provides a more complete view of brain activity, designed to help clinicians identify patterns, differentiate

Firefly Neuroscience partners with Next Health on cognitive health platform

Tue, 28 Jul 2026 07:50:25 -0400

Firefly Neuroscience, Inc. (NASDAQ: AIFF) and Next Health announced a partnership to launch a cognitive health platform that combines Firefly's FDA-cleared EEG/ERP brain biomarker technology with personalized peptide protocols, according to a press release issued July 28, 2026.

The platform is intended to give physicians objective measures of brain function to help guide and monitor cognitive therapies. The companies plan to develop standardized clinical protocols integrating Firefly's AI-powered Evoke System with provider-guided peptide therapies across Next Health's network of longevity clinics.

The announcement follows a recommendation by an FDA Advisory Committee to add six therapeutic peptides — including Epitalon and Semax —

Firefly Neuroscience (NASDAQ: AIFF) and Next Health Launch Precision Cognitive Health Initiative as FDA Advisory Committee’s Recommendation Backs Broader Access to Key Neuroprotective Peptides

Tue, 28 Jul 2026 07:50:00 -0400

– FDA Advisory Committee voted to recommend easing compounding restrictions for six peptides, including Epitalon and Semax, late last week –

– These two peptides have attracted growing scientific interest for their potential neuroprotective and cognitive-supportive properties –

– Collaboration represents a significant step toward making precision cognitive care more measurable, scalable, and clinically actionable –

KENMORE, N.Y. and LOS ANGELES, July 28, 2026 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly”) (NASDAQ: AIFF), an Artificial Intelligence ("AI") company advancing precision neuroscience, and Next Health, a global leader in health optimization and

Firefly Neuroscience (NASDAQ: AIFF) and Next Health Launch Precision Cognitive Health Initiative as FDA Advisory Committee’s Recommendation Backs Broader Access to Key Neuroprotective Peptides

Tue, 28 Jul 2026 07:50:00 -0400

– FDA Advisory Committee voted to recommend easing compounding restrictions for six peptides, including Epitalon and Semax, late last week –

– These two peptides have attracted growing scientific interest for their potential neuroprotective and cognitive-supportive properties –

– Collaboration represents a significant step toward making precision cognitive care more measurable, scalable, and clinically actionable –

Firefly Neuroscience (NASDAQ: AIFF) and Next Health Launch Precision Cognitive Health Initiative as FDA Advisory Committee’s Recommendation Backs Broader Access to Key Neuroprotective Peptides

Tue, 28 Jul 2026 07:50:00 -0400

– FDA Advisory Committee voted to recommend easing compounding restrictions for six peptides, including Epitalon and Semax, late last week –

– These two peptides have attracted growing scientific interest for their potential neuroprotective and cognitive-supportive properties –

– Collaboration represents a significant step toward making precision cognitive care more measurable, scalable, and clinically actionable –

Firefly Neuroscience (NASDAQ: AIFF) and Next Health Launch Precision Cognitive Health Initiative as FDA Advisory Committee’s Recommendation Backs Broader Access to Key Neuroprotective Peptides

Tue, 28 Jul 2026 07:50:00 -0400

– FDA Advisory Committee voted to recommend easing compounding restrictions for six peptides, including Epitalon and Semax, late last week –

– These two peptides have attracted growing scientific interest for their potential neuroprotective and cognitive-supportive properties –

– Collaboration represents a significant step toward making precision cognitive care more measurable, scalable, and clinically actionable –